Atai Beckley Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health ...
Latest News
2 months ago · zacks.com
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock?
2 months ago · zacks.com
Lilly Builds Neuroscience into a New Long-Term Growth DriverLilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
3 months ago · zacks.com
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should KnowThe mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 months ago · fool.com
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares.
3 months ago · globenewswire.com
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli LillyMONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive $6.75 per share in cash, plus a contingent value right (“CVR”) worth up to an additional $2.50 per share.
3 months ago · zacks.com
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 months ago · zacks.com
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley BuyoutLLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
4 months ago · proactiveinvestors.com
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says JefferiesAtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.
4 months ago · prnewswire.com
Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders?/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
4 months ago · fool.com
Why AtaiBeckley Stock Soared TodayAtaiBeckley is developing a promising depression treatment. Eli Lilly has long been a leader in neuroscience.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ATAI